Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
Abstract Background Day‐to‐day variability impacts safety of insulin therapy and the choice of monitoring strategies. Side‐by‐side comparisons of insulin formulations in diabetic dogs are scarce. Hypothesis/Objectives Insulin glargine 300 U/mL (IGla300) and insulin degludec (IDeg) are associated wit...
Main Authors: | Michelle Miller, Jully Pires, Katti Crakes, Rachel Greathouse, Nina Quach, Chen Gilor |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-09-01
|
Series: | Journal of Veterinary Internal Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1111/jvim.16178 |
Similar Items
-
Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
by: Yuji Kawaguchi, et al.
Published: (2019-11-01) -
Insulin degludec is a new ultra-long-acting insulin analogue
by: Ivan Ivanovich Dedov, et al.
Published: (2014-06-01) -
Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open‐label, cross‐over study using continuous glucose monitoring profiles
by: Yuji Kawaguchi, et al.
Published: (2019-03-01) -
Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
by: Silvio Buscemi, et al.
Published: (2019-11-01) -
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
by: Ivan Ivanovich Dedov, et al.
Published: (2014-12-01)